logo

Intranasal Antiviral Vaccine Platform Clinical Trial Manufacturing

Sector: Manufacturing (Industrial) • Location: College Station, Texas, United States

Project
Under Construction

Matica Bio is partnering with VaxDome to develop and manufacture VaxDome's novel antigen-agnostic antiviral-vaccine hybrid candidates for clinical trials. The project involves process development, analytical development, and production of clinical materials at Matica Bio's facility in College Station, Texas.

Status
Under Construction
Sector
Manufacturing (Industrial)
Location
College Station, Texas, United States of America
Updated
22 Jul 2026
Source
BioPharma APAC

ConstructChat

Ask ConstructChat about Intranasal Antiviral Vaccine Platform Clinical Trial Manufacturing

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Intranasal Antiviral Vaccine Platform Clinical Trial Manufacturing” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in College Station, Texas, United States. Taiyo aggregates data on it from BioPharma APAC.

Participants

Not available for this record.

Status

Original status

under construction

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Matica Bio is partnering with VaxDome to develop and manufacture VaxDome's novel antigen-agnostic antiviral-vaccine hybrid candidates for clinical trials. The project involves process development, analytical development, and production of clinical materials at Matica Bio's facility in College Station, Texas.

Original sector

Biopharma Manufacturing

Location

Country

United States of America (USA)

State

Texas

City

College Station

Source

Source

BioPharma APAC

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial)

Article published date

2026-07-12

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project